Study of DEM301 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called DEM301 for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if DEM301 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced colorectal cancer that has gotten worse after standard treatment, or you could not receive standard treatment.
- You are expected to live at least 3 months.
- You are able to take care of yourself (Eastern Cooperative Oncology Group [ECOG] score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You agree to provide a tumor sample (biopsy) if needed for testing.
- You have adequate bone marrow, liver, and kidney function.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
- You are willing and able to follow the study schedule and requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This study tests an experimental drug (DES-1357) for people with a specific type of advanced colorectal cancer that has not responded to previous treatments. The drug is designed to target tumors with a genetic mismatch repair deficiency, potentially helping to slow or stop cancer growth.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.